Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Ragothaman Srinivasan

DARK SECRETS: Ayala reveals positive results from phase 2 3 desmoid tumors study | Rare Historical Photos

Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) announced positive interim results from Part A of the ongoing RINGSIDE Pivotal Phase 2/3 clinical trial evaluating AL102 in desmoid tumors.

The company revealed that the positive results from Part A will be used to determine the dose of AL102 to be evaluated in Part B of RINGSIDE Study.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.